The Everest Group ranking evaluates vendors based on a weighted composite score, prioritizing market adoption, scale, and the ability to deliver tangible outcomes for pharmaceutical clients. ACTO’s inclusion arrives as the industry pivots from simple workflow digitization toward connected, AI-enabled execution. Durga Ambati, Vice President at Everest Group, noted that the company’s sustained investment in simulated coaching and knowledge assistance has created a distinct position within the commercial technology ecosystem.
In section Releases
ACTO Named Among Top 50 Pharmaceutical Technology Providers
Toronto-based ACTO has secured a spot on Everest Group’s Top 50 Pharmaceutical Technology Providers list for 2026. The recognition highlights the company’s specialized focus on AI-driven field excellence, positioning its agentic workflows and platform integration as critical components for life sciences companies navigating complex regulatory environments.
ACTO’s platform—which currently serves 14 of the top 50 pharmaceutical companies—focuses on augmenting customer-facing professionals through role-based SuperAgents. These agents are designed to orchestrate multi-step workflows while adhering to strict governance and traceability standards. According to CEO Parth Khanna, the firm’s strategy remains rooted in its exclusive focus on the life sciences sector, allowing for deep integration with existing systems like Veeva and Salesforce. This validation from Everest Group underscores the growing demand for tools that unify fragmented data to improve stakeholder engagement and commercial performance.
Comments (0)
No comments yet. Be the first!